| Literature DB >> 23766851 |
Jie Liu1, Kai Connie Wu, Yuan-Fu Lu, Edugie Ekuase, Curtis D Klaassen.
Abstract
To investigate the role of Nrf2 as a master defense against the hepatotoxicity produced by various chemicals, Nrf2-null, wild-type, Keap1-knock down (Keap1-Kd) and Keap1-hepatocyte knockout (Keap1-HKO) mice were used as a "graded Nrf2 activation" model. Mice were treated with 14 hepatotoxicants at appropriate doses, and blood and liver samples were collected thereafter (6 h to 7 days depending on the hepatotoxicant). Graded activation of Nrf2 offered a Nrf2-dependent protection against the hepatotoxicity produced by carbon tetrachloride, acetaminophen, microcystin, phalloidin, furosemide, cadmium, and lithocholic acid, as evidenced by serum alanine aminotransferase (ALT) activities and by histopathology. Nrf2 activation also offered moderate protection against liver injury produced by ethanol, arsenic, bromobenzene, and allyl alcohol but had no effects on the hepatotoxicity produced by D-galactosamine/endotoxin and the Fas ligand antibody Jo-2. Graded Nrf2 activation reduced the expression of inflammatory genes (MIP-2, mKC, IL-1 β , IL-6, and TNF α), oxidative stress genes (Ho-1, Egr1), ER stress genes (Gadd45 and Gadd153), and genes encoding cell death (Noxa, Bax, Bad, and caspase3). Thus, this study demonstrates that Nrf2 prevents the liver from many, but not all, hepatotoxicants. The Nrf2-mediated protection is accompanied by induction of antioxidant genes, suppression of inflammatory responses, and attenuation of oxidative stress.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23766851 PMCID: PMC3676920 DOI: 10.1155/2013/305861
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
The basal levels of the Nrf2 and Nrf2-targeted genes in the “graded Nrf2 activation” model.
| Nrf2-null | Wild-type | Keap1-Kd | Keap1-HKO | |
|---|---|---|---|---|
| Nrf2-related | ||||
| Nqo1 | 0.037 ± 0.007* | 0.29 ± 0.02 | 0.74 ± 0.12* | 3.17 ± 0.36* |
| Nrf2 | 0.002 ± 0.001* | 0.07 ± 0.02 | 1.46 ± 0.05* | 2.10 ± 0.24* |
| Gclc | 3.84 ± 0.86* | 7.01 ± 1.11 | 10.1 ± 1.37* | 27.2 ± 2.49* |
| GSH-related | ||||
| Gsr | 0.11 ± 0.01* | 0.21 ± 0.01 | 0.03 ± 0.01 | 0.06 ± 0.01* |
| Gsta1 | 0.45 ± 0.11* | 2.77 ± 1.43 | 15.4 ± 3.58* | 51.1 ± 7.25* |
| Gsta4 | 1.48 ± 0.39* | 2.97 ± 1.14 | 4.63 ± 1.02 | 7.93 ± 1.55* |
| Gstmu | 20.7 ± 1.43* | 107 ± 28.3 | 544 ± 98.2* | 1547 ± 350* |
| Gstpi | 101 ± 22.2 | 7.01 ± 1.11 | 10.1 ± 1.37* | 27.2 ± 2.49* |
| Gpx2 | 0.02 ± 0.01 | 0.04 ± 0.03 | 0.06 ± 0.01 | 2.15 ± 0.81* |
| Acute-phase | ||||
| Mt-1 | 4.22 ± 0.93 | 3.48 ± 1.11 | 20.1 ± 5.43* | 27.4 ± 2.49* |
| Ho-1 | 0.46 ± 0.06 | 0.64 ± 0.03 | 0.87 ± 0.15* | 1.23 ± 0.37* |
Data are % of the housekeeping gene G3PDH and represent mean ± SEM of serum ALT values (n = 6–10), *significantly different from wild-type mice, P < 0.05.
The “graded Nrf2 activation” model in protecting against hepatotoxicants.
| Hepatotoxicants | Dose, route, and time | Nrf2-null | Wild-type | Keap1-Kd | Keap1-HKO | References |
|---|---|---|---|---|---|---|
| Carbon tetrachloride | 25 | 4610 ± 920 | 2970 ± 690 | 2110 ± 464 | 503 ± 301* | Unpublished |
| Acetaminophen | 500 mg/kg, ip, 8 h | 1010 ± 385 | 615 ± 165 | 266 ± 93* | 198 ± 43* | Unpublished |
| Microcystin | 50 | 1010 ± 385 | 615 ± 165 | 266 ± 93* | 198 ± 43* | Unpublished |
| Phalloidin | 1.5 mg/kg, ip, 8 h | 4130 ± 705 | 3630 ± 1185 | 1410 ± 348 | 210 ± 87* | Unpublished |
| Furosemide | 250 mg/kg, ip, 18 h | 1095 ± 365 | 570 ± 393 | 40 ± 8* | 35 ± 5* | Unpublished |
| Cadmium | 3.5 mg/kg, ip, 8 h | 995 ± 152 | 675 ± 98 | 201 ± 21* | 111 ± 15* | Wu et al., 2012a |
| Arsenic | 100 umol/kg, ip, 8 h | 165 ± 52 | 120 ± 53 | 66 ± 29 | 52 ± 18* | Unpublished |
| Ethanol | 5 g/kg, po, 6 h | 70 ± 20 | 88 ± 25 | 46 ± 11 | 38 ± 5* | Wu et al., 2012b |
| Diquat | 125 mg/kg, ip, 6 h | 604 ± 65 | 412 ± 48 | 302 ± 16* | N.D. | Wu et al., 2012c |
| Bromobenzene | 0.7 ml/kg, ip, 24 h | 1650 ± 235 | 1550 ± 211 | N.D. | 175 ± 35* | Unpublished |
| Allyl Alcohol | 85 mg/kg, ip, 24 h | 1130 ± 211 | 1050 ± 330 | N.D. | 220 ± 65* | Unpublished |
| Lithocholic acid | 0.4% in diet, 7 d | 1390 ± 216 | 985 ± 211 | 450 ± 112 | 105 ± 25* | Unpublished |
| D-Gal/LPS | 400 mg/10 ug/kg, ip, 6 h | 4630 ± 1250 | 3730 ± 660 | 5430 ± 1005 | 3650 ± 535 | Unpublished |
| Fas Jo2 antibody | 5 | 4815 ± 1310 | 5530 ± 2105 | 5545 ± 1950 | 6170 ± 2510 | Unpublished |
Data represent mean ± SEM of serum ALT values (n = 6–10), *significantly different from wild-type mice, P < 0.05. N.D.: not detected.
Figure 1Histological analysis of livers from Nrf2-null, wild-type, and Keap1-HKO mice treated with CCl4 (25 μL/kg, ip, 16 h), acetaminophen (APAP, 400 mg/kg, ip for 8 h), microcystin (50 μg/kg, ip, 8 h), phalloidin (1.5 mg/kg, ip, 8 h), furosemide (250 mg/kg, ip 24 h), and D-galactosamine/endotoxin (400 mg/10 μg/kg, ip, 8 h). Arrows indicate hemorrhage and inflammation and arrowheads indicate hepatocellular necrosis (200x).
Inflammatory gene expressions under the challenge of hepatotoxicants.
| Nrf2-null | Wild-type | Keap1-Kd | Keap1-HKO | |
|---|---|---|---|---|
| MIP-2 | +++ | ++ | + | ± |
| mKC | +++ | ++ | + | ± |
| ICAM1 | ++ | ++ | + | + |
| IL-1 | +++ | ++ | + | ± |
| IL-6 | ++ | + | ± | ± |
| TNF | ++ | + | ± | ± |
| Egr1 | ++ | ++ | + | + |
| Ho-1 | +++ | ++ | + | + |
MIP-2: macrophage inflammatory protein 2; mKC: mouse keratinocyte-derived chemokine; IL-1β: interleukin-1β; IL-6: interleukin-6; TNFα: tumor necrosis factor α. Ho-1: heme oxygenase-1. “+++” indicates significant increase; “++” indicates moderate increase; “+” indicates slight mild increase; “±” indicates slight increase. These inflammatory gene expression profiles are similar for the hepatotoxicity produced by acetaminophen, carbon tetrachloride, microcystin, phalloidin, and furosemide.
Expression of DNA damage genes and genes of cell death.
| Nrf2-null | Wild-type | Keap1-Kd | Keap1-HKO | |
|---|---|---|---|---|
| DNA damage | ||||
| Gadd45 | ++++ | +++ | ++ | + |
| Gadd153 | ++++ | +++ | ++ | + |
| Apoptosis | ||||
| Noxa | +++ | ++ | + | + |
| Bax | ++ | ++ | + | + |
| Bad | ++ | ++ | + | + |
| Casp3 | ++ | ++ | + | + |
Gadd45: the growth arrest and DNA damage-inducible 45 proteins; Gadd153/Chop10: C/EBP homologous protein 10; Noxa: a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis; Bax: Bcl-2 associated protein X; Bad: BCL2-associated agonist of cell death; Casp3: caspases 3. “+++” indicates significant increase; “++” indicates moderate increase; “+” indicates slight mild increase. These inflammatory gene expression profiles are similar for the hepatotoxicity produced by acetaminophen, carbon tetrachloride, microcystin, phalloidin, and furosemide.